Education
About Us
Working with TipRanks
Follow Us
Inmune Bio (INMB)
NASDAQ:INMB
INMB Stock Chart & Stats
$1.53
-$0.22(-3.95%)
At close: 4:00 PM EST
$1.53
-$0.22(-3.95%)
Day’s Range― - ―
52-Week Range$1.21 - $11.64
Previous CloseN/A
Volume114.20K
Average Volume (3M)380.68K
Market Cap
$33.63M
Enterprise Value$6.98M
Total Cash (Recent Filing)$27.73M
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding26,585,258
10 Day Avg. Volume574,829
30 Day Avg. Volume380,682
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)2.90
Price to Sales (P/S)6652.75
P/FCF Ratio-2.79
Enterprise Value/Market Cap0.21
Enterprise Value/Revenue139.53
Enterprise Value/Gross Profit317.11
Enterprise Value/Ebitda-0.21
Forecast
1Y Price Target
$8.00Price Target Upside422.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.99
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker-driven EfficacyA biomarker-enriched strategy focusing on patients with multiple inflammation-linked markers showed prior cognitive and behavioral improvements, indicating that targeting this subgroup could yield stronger efficacy signals in confirmatory studies.
Cash RunwayReported cash resources sufficient to support upcoming clinical and regulatory milestones reduce near-term financing pressure and support continued execution of pivotal development activities.
Regulatory PathwayFDA alignment on an integrated mid-to-late-stage registration study for XPro creates a clearer development path where a confirmatory readout can expand directly into a registration trial using a widely accepted cognitive endpoint, enhancing prospects for regulatory review.
Bears Say
Clinical Trial Outcome RiskA prior mid-stage Alzheimer's trial missed its primary goals, increasing the risk that future studies will face greater regulatory and scientific scrutiny.
Investor Sentiment RiskHeightened investor sensitivity after the missed endpoints could amplify negative market reactions to any additional delays, ambiguous results, or funding concerns.
Share Price VolatilityThe trial miss contributed to a share price pullback, raising the chance of elevated market volatility around subsequent trial updates.
Inmune Bio News
INMB FAQ
What was Inmune Bio’s price range in the past 12 months?
Inmune Bio lowest stock price was $1.21 and its highest was $11.64 in the past 12 months.
What is Inmune Bio’s market cap?
Inmune Bio’s market cap is $33.63M.
When is Inmune Bio’s upcoming earnings report date?
Inmune Bio’s upcoming earnings report date is May 06, 2026 which is in 60 days.
How were Inmune Bio’s earnings last quarter?
Currently, no data Available
Is Inmune Bio overvalued?
According to Wall Street analysts Inmune Bio’s price is currently Undervalued.
Does Inmune Bio pay dividends?
Inmune Bio does not currently pay dividends.
What is Inmune Bio’s EPS estimate?
Inmune Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inmune Bio have?
Inmune Bio has 26,585,258 shares outstanding.
What happened to Inmune Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Inmune Bio?
Currently, no hedge funds are holding shares in INMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inmune Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (422.88% Upside)
$8.00 (422.88% Upside)
Blogger Sentiment
Bullish
INMB Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-84.53%
12-Months-Change
Fundamentals
Return on Equity
-155.77%
Trailing 12-Months
Asset Growth
-36.80%
Trailing 12-Months
Company Description
Inmune Bio
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
INMB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive sentiment with significant advancements in CORDStrom and INKmune platforms, as well as promising regulatory pathways for XPro. Financial results showed improved operating efficiency, although challenges with XPro trial results and regulatory delays were noted.View all INMB earnings summariesINMB Stock 12 Month Forecast
Average Price Target
$8.00
▲(422.88% Upside)
Technical Analysis
Veru
―
Karyopharm Therapeutics
―
Cue Biopharma
―
Celularity
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
11.17%
Insiders
4.57% Mutual Funds
0.87% Other Institutional Investors
77.60% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---